Edgar Filing: VISX INC

Visx, Inc., Form 10-Q dated March 31, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q


(X)		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2003


( )		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 1-10694

VISX, INCORPORATED

(Exact name of registrant as specified in its charter)


Delaware		06-1161793

(State or other Jurisdiction of Incorporation or Organization)		(IRS Employer Identification No.)

3400 Central Expressway, Santa Clara, California 95051-0703

(Address of principal executive offices) (Zip Code)

(Registrant’s telephone number, including area code): (408) 733-2020

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes (X) No ( )

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes (X) No ( )

Total number of shares of common stock outstanding as of April 30, 2003: 51,355,375.

Page 1 of 23

TABLE OF CONTENTS


	PART I. FINANCIAL INFORMATION
	Item 1. Condensed Consolidated Interim Financial Statements
		CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS
		CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS
		CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
		NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
	Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
		Overview
		Results of Operations
		Liquidity and Capital Resources
		Critical Accounting Policies
	Item 3. Quantitative and Qualitative Disclosures about Market Risk
	Item 4. Disclosure Controls and Procedures
	PART II. OTHER INFORMATION
	Item 1. Legal Proceedings
	Item 5. Other Information
	Item 6. Exhibits and Reports on Form 8-K
SIGNATURES
EXHIBIT 99.1

VISX, INCORPORATED
TABLE OF CONTENTS


		Page
PART I.	FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Interim Financial Statements
	Condensed Consolidated Interim Balance Sheets as of March 31, 2003 and December 31, 2002	3
	Condensed Consolidated Interim Statements of Operations for the Three Months Ended March 31, 2003 and 2002	4
	Condensed Consolidated Interim Statements of Cash Flows for the Three Months Ended March 31, 2003 and 2002	5
	Notes to Condensed Consolidated Interim Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations
	Overview	11
	Results of Operations	12
	Liquidity and Capital Resources	14
	Critical Accounting Policies	15
	Risk Factors	17
Item 3.	Quantitative and Qualitative Disclosure about Market Risk	17
Item 4.	Disclosure Controls and Procedures	17
PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	18
Item 5.	Other Information	19
Item 6.	Exhibits and Reports on Form 8-K	19
SIGNATURES		20

Page 2 of 23

PART I. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Interim Financial Statements

VISX, INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS
(In thousands, except share and per share amounts)


					March 31,			December 31,
					2003			2002

					(unaudited)
				ASSETS
Current Assets:
	Cash and cash equivalents				$	36,828		$	37,687
	Short-term investments					93,057			85,268
	Accounts receivable, net of allowance for doubtful accounts of $2,763 and $2,563, respectively					25,927			24,559
	Inventories					14,244			12,751
	Deferred tax assets and prepaid expenses					20,128			23,488

		Total current assets				190,184			183,753
Property and Equipment, net						7,230			6,498
Long-Term Deferred Tax and Other Assets						9,440			10,341

					$	206,854		$	200,592

			LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
	Accounts payable				$	5,617		$	4,341
	Accrued liabilities and other current liabilities					40,621			41,061

		Total current liabilities				46,238			45,402

Stockholders’ Equity:
	Common stock: $.01 par value, 180,000,000 shares authorized; 64,990,089 shares issued					650			650
	Additional paid-in capital					202,573			202,700
	Treasury stock, at cost 13,639,256 and 13,652,256 shares, respectively					(208,549	)		(208,748	)
	Accumulated other comprehensive income					1,799			1,921
	Retained earnings					164,143			158,667

		Total stockholders’ equity				160,616			155,190

					$	206,854		$	200,592

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Page 3 of 23

VISX, INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)


			Three months ended
			March 31,

			2003		2002

			(unaudited)
Revenues:
	System revenues		$	9,926	$	9,915
	Service and parts revenues			4,830		5,090
	License and other revenues			19,677		21,580

		Total revenues		34,433		36,585

Costs and Expenses:
	Cost of system revenues			8,295		8,181
	Cost of service and parts revenues			3,697		3,216
	Cost of license and other revenues			1,193		1,207
	Selling, general and administrative			9,093		10,518
	Research, development and regulatory			4,046		4,245

	Total costs and expenses			26,324		27,367

Income From Operations				8,109		9,218
	Interest and other income			943		1,531

Income Before Provision For Income Taxes				9,052		10,749
	Provision for income taxes			3,576		4,246

Net Income			$	5,476	$	6,503

Earnings Per Share
	Basic		$	0.11	$	0.12

	Diluted		$	0.11	$	0.12

Shares Used For Earnings Per Share
	Basic			51,342		54,509

	Diluted			51,805		55,581

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Page 4 of 23

VISX, INCORPORATED AND SUBSIDIARIES


		CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
		(In thousands)


				Three months ended March 31,

				2003			2002

				(unaudited)
Cash flows from operating activities:
	Net income			$	5,476		$	6,503
	Adjustments to reconcile net income to net cash provided by operating activities:
		Depreciation and amortization			1,275			905
		Provision for doubtful accounts receivable			209			200
		Increase (decrease) in operating assets and liabilities:
			Accounts receivable		(1,577	)		2,801
			Inventories		(3,191	)		707
			Deferred tax assets and prepaid expenses		3,360			4,420
			Long-term deferred tax and other assets		872			1,233
			Accounts payable		1,276			1,978
			Accrued liabilities		(440	)		1,731

		Net cash provided by operating activities			7,260			20,478

Cash flows from investing activities:
	Capital expenditures				(280	)		(542	)
	Purchase of short-term investments				(14,882	)		(13,105	)
	Proceeds from maturities of short-term investments				6,971			23,523

		Net cash provided by (used in) investing activities			(8,191	)		9,876

Cash flows from financing activities:
	Exercise of stock options				72			2,572
	Repurchase of common stock				—			(16,238	)

		Net cash provided by (used in) financing activities			72			(13,666	)

Effect of exchange rate changes					—			9

Net increase (decrease) in cash and cash equivalents					(859	)		16,697
Cash and cash equivalents, beginning of period					37,687			15,349

Cash and cash equivalents, end of period				$	36,828		$	32,046

Supplemental Cash Flow Information:
	Income taxes paid			$	(10)		$	91
	Non-cash investing activities:
		Inventory transferred to property and equipment under operating leases			1,698			1,284

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Page 5 of 23

VISX, INCORPORATED AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
March 31, 2003
(Unaudited)

1. Basis of Presentation:

We prepared our Condensed Consolidated Interim Financial Statements in conformity with Securities and Exchange Commission rules and regulations. Accordingly, we condensed or omitted certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States. Please read our 2002 Annual Report on Form 10-K to gain a more complete understanding of these interim financial statements.

We included in these interim financial statements all adjustments (consisting primarily only of normal recurring adjustments) necessary to present fairly our results for the interim period. Our interim financial statements have not been audited.

Certain reclassifications were made to prior year financial data to conform with current year presentation.

2. Earnings Per Share:

Basic earnings per share (“EPS”) equals net income divided by the weighted average number of common shares outstanding. Diluted EPS equals net income divided by the weighted average number of common shares outstanding plus dilutive potential common shares calculated in accordance with the treasury stock method. All amounts in the following table are in thousands, except per share data, and are unaudited.


		Three Months Ended
		March 31,

		2003		2002

NET INCOME		$	5,476	$	6,503

BASIC EARNINGS PER SHARE
	Income available to common shareholders	$	5,476	$	6,503
	Weighted average common shares outstanding		51,342		54,509

	Basic Earnings Per Share	$	0.11	$	0.12

DILUTED EARNINGS PER SHARE
	Income available to common shareholders	$	5,476	$	6,503

	Weighted average common shares outstanding		51,342		54,509
	Dilutive potential common shares from stock options		463		1,072

	Weighted average common shares and dilutive potential common shares		51,805		55,581

	Diluted Earnings Per Share	$	0.11	$	0.12

Options to purchase 6,597,000 and 5,303,000 shares during the three-month periods ended March 31, 2003 and 2002, respectively, were excluded from the computation of diluted EPS because the weighted average exercise prices for these options of $21.51 and $25.17, respectively, were greater than the average market price of our common stock during these periods.

Page 6 of 23

3. Stock-Based Employee Compensation

We account for stock-based employee compensation arrangements using the intrinsic value method in accordance with the provisions of Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” (“APB 25”) and Financial Accounting Standards Board (“FASB”) Interpretation No. 44 (“FIN 44”), “Accounting for Certain Transactions Involving Stock Compensation – an Interpretation of APB No. 25” and comply with the disclosure provisions of Statement of Financial Accounting Standards No. 148, “Accounting For Stock-Based Compensation – Transition and Disclosure” (“SFAS 148”). In accordance with APB 25 and FIN 44, we record no stock-based employee compensation cost in our net income because (1) all options granted under our stock option plans have an exercise price equal to the market value of the underlying common stock on the date of grant and (2) stock purchased through our Employee Stock Purchase Plan is priced at 85% of the fair market value of the stock on the first day or the end of each six month segment of a two year offering period. The following table illustrates the effect on net income and earnings per share if we had applied the fair value recognition provisions of Statement of Financial Accounting Standards No. 123, “Accounting for Stock-Based Compensation” (“SFAS 123”), to stock-based employee compensation (unaudited, in thousands, except per share data).


		Three Months Ended
		March 31,

		2003		2002

Net Income	As Reported	$	5,476	$	6,503
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects			(1,817)		(2,252)

Net Income	Pro Forma	$	3,659	$	4,251

Basic Earnings Per Share	As Reported	$	0.11	$	0.12
	Pro Forma		0.07		0.08
Diluted Earnings Per Share	As Reported	$	0.11	$	0.12
	Pro Forma		0.07		0.08

Under SFAS 123 the fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model. The following weighted average assumptions were used for grants issued in 2003 and 2002, respectively: risk-free interest rates of 2.4% and 4.1%, expected volatility of 73% and 76%, no expected dividends, and an expected life of 1.5 and 1.5 years beyond the vest date for each year’s vesting increment of an option.

These pro forma amounts may not be representative of the effects for future years as options vest over several years and additional awards are generally made each year.

4. Inventories (in thousands):


	March 31,		December 31,
	2003		2002

	(Unaudited)
Raw materials and subassemblies	$	8,314	$	8,108
Work in process		1,709		1,563
Finished goods		4,221		3,080

	$	14,244	$	12,751

Page 7 of 23

5. Comprehensive Income (unaudited, in thousands):


		Three Months Ended
		March 31,

		2003			2002

NET INCOME		$	5,476		$	6,503
OTHER COMPREHENSIVE INCOME
	Decrease in accumulated unrealized holding gains on available-for-sale securities		(122	)		(1,235	)
	Change in accumulated foreign currency translation adjustment		—			9

COMPREHENSIVE INCOME		$	5,354		$	5,277

6. Warranty Obligations

Changes in product warranty obligations for the periods ended March 31, 2003 and 2002 are as follows (unaudited, in thousands):


	Three Months Ended
	March 31,

	2003			2002

Balance as of the beginning of the period	$	1,963		$	1,768
Expense accrued for new warranties		768			926
Cost of services provided		(751	)		(1,049	)

Balance as of the end of the period	$	1,980		$	1,645

7. Stock Repurchase Program

On April 4, 2001, our Board of Directors authorized a new Stock Repurchase Program under which up to 10 million shares of VISX common stock may be repurchased. In accordance with the April 4, 2001 authorization and applicable securities laws, through purchases on the open market we have repurchased 7.0 million shares cumulatively through March 31, 2003 at a total cost of $90.4 million, respectively. Accordingly, 3.0 million shares remain available as of March 31, 2003 for repurchase under the Board of Directors’ April 2001 authorization.

8. Significant Customer

A significant portion of our revenues is derived from sales to TLC Vision Corporation (“TLC”), formed in May 2002 through the merger of TLC Laser Eye Centers, Inc. and Laser Vision Centers, Inc., both long-term customers of ours. Sales to the combined company, TLC, accounted for 13% and 16% of total revenues in the first quarter of 2003 and 2002, respectively.

9. New Accounting Pronouncements

In June 2001, the FASB issued Statement No. 143, “Accounting for Asset Retirement Obligations” (“SFAS 143”). SFAS 143 requires that the fair value of a liability for a retirement obligation be recognized in the period in which it is incurred, if a reasonable estimate of the fair value can be made, and expense charged over the life of the asset. The statement is effective for financial statements issued

Page 8 of 23

for fiscal years beginning after June 15, 2002. The adoption of SFAS 143 did not have a material impact on our financial position or results of operations.

In July 2002, the FASB issued Statement No. 146, “Accounting for Costs Associated with Exit or Disposal Activities” (“SFAS 146”) and nullified EITF Issue No. 94-3 “Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring”. SFAS 146 requires that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred, whereas EITF No. 94-3 had recognized the liability at the commitment date to an exit plan. We are required to adopt the provisions of SFAS 146 effective for exit or disposal activities initiated after December 31, 2002. The adoption of SFAS 146 did not have a material impact on our financial position or results of operations.

In November 2002, the FASB issued FASB Interpretation No. 45 (“FIN 45”), “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others.” FIN 45 requires that a liability be recorded in the guarantor’s balance sheet upon issuance of a guarantee. In addition, FIN 45 requires disclosures about the guarantees that an entity has issued, including a rollforward of the entity’s product warranty liabilities. The disclosure requirements are effective for financial statements issued after December 15, 2002 and the recognition/measurement requirements are effective on a prospective basis for guarantees issued or modified after December 31, 2002. The application of the requirements of FIN 45 did not have a material impact on our financial position or results of operations.

In November 2002, the EITF reached a consensus on Issue No. 00-21, “Revenue Arrangements with Multiple Deliverables.” EITF Issue No. 00-21 provides guidance on how to account for arrangements that involve the delivery or performance of multiple products, services and/or rights to use assets. The provisions of EITF Issue No. 00-21 will apply to revenue arrangements entered into in fiscal periods beginning after June 15, 2003. We are currently evaluating the effect that the adoption of EITF Issue No. 00-21 will have on our results of operations and financial position.

In December 2002, the FASB issued SFAS No. 148, “Accounting for Stock-Based Compensation, Transition and Disclosure.” SFAS No. 148 provides alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. SFAS No. 148 also requires that disclosures of the pro forma effect of using the fair value method of accounting for stock-based employee compensation be displayed more prominently and in a tabular format. Additionally, SFAS No. 148 requires disclosure of the pro forma effect in interim financial statements. The transition and annual disclosure requirements of SFAS No. 148 are effective for fiscal years ending after December 15, 2002. The interim disclosure provisions are effective for financial reports containing financial statements for interim periods beginning after December 15, 2002. As we did not make a voluntary change to the fair value based method of accounting for stock-based employee compensation in 2002, the adoption of SFAS No. 148 did not have a material impact on our financial position or results of operations. The disclosure requirements have been adopted and incorporated in the footnotes to these financial statements.

In January 2003, the FASB issued FASB Interpretation No. 46 (“FIN 46”), “Consolidation of Variable Interest Entities, an Interpretation of ARB No. 51.” FIN 46 requires certain variable interest entities to be consolidated by the primary beneficiary of the entity if the equity investors in the entity do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties. FIN 46 is effective for all new variable interest entities created or acquired after January 31, 2003. For variable interest entities created or acquired prior to February 1, 2003, the provisions of FIN 46 must be applied

Page 9 of 23

for the first interim or annual period beginning after June 15, 2003. The adoption of FIN 46 did not have a material impact on our financial position or results of operations.

10. Subsequent Event

In April 2003, we acquired technology, including patents and other assets associated with our WaveScan WaveFront® System (“WaveScan System”) from 20/10 Perfect Vision Optische Gerate GmbH. We paid $5.9 million for this technology, which was previously licensed to us under an exclusive licensing agreement that is superseded by the acquisition.

Page 10 of 23

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Report contains forward-looking statements, including but not limited to: the anticipated approval by the Food and Drug Administration (“FDA”) of our CustomVue^TM procedure which provides for the treatment of patients using data from our WaveScan WaveFront® System (“WaveScan System”); declining laser upgrade revenue; our belief that a rebound in the U.S. economy and increases in consumer confidence will provide renewed support for the U.S. laser vision correction market in the future; our belief that ongoing technical advances (including our CustomVue™ procedure) have the potential to improve a person’s vision beyond that which can be obtained with contact lenses or glasses and will reduce concerns perceived by some consumers; research and development and regulatory expenditures; the sufficiency of our cash flow from operations combined with our existing cash, cash equivalents and short-term investments to meet our needs during the coming twelve months; and our belief that legal actions will not materially affect our business. These forward-looking statements are estimates reflecting the best judgment of our senior management, and they involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. The risks and uncertainties include the potential reduction in demand for our equipment and upgrades, and the potential decline in demand for procedures caused by the continued weakness in the economy, consumer confidence and stock markets in the United States. In addition, please see the disclosure under the caption “Risk Factors” at the end of Item 2. Moreover, we caution you not to place undue reliance on these forward-looking statements, which speak only as of the date they were made. We do not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events.

The laser vision correction industry is evolving rapidly. Economic, market, and technology changes frequently affect VISX and could harm our business in the future. If any of the risks referred to above were to materialize, orders and revenues for the VISX STAR Excimer Laser System™ (“VISX STAR System”) and VisionKey® Cards could fluctuate or decline. Accordingly, our past results may not be useful in predicting our future results.

Overview

VISX, Incorporated (“VISX”), a Delaware corporation organized in 1988, is a worldwide leader in the design and development of proprietary technologies and systems for laser vision correction. We sell products worldwide and generate the majority of our revenue through the sale of VisionKey Cards that are required to perform laser vision correction procedures on the VISX STAR System. We have also licensed our technology to other excimer laser system companies and generally receive royalties from the sale of their systems outside the U.S. and from procedures that are performed in the U.S. using their systems.

The FDA and comparable international regulatory agencies have approved the VISX STAR System for use in the treatment of most types of refractive vision disorders including nearsightedness, farsightedness, and astigmatism. The FDA has also approved our WaveScan System, a diagnostic device that measures refractive errors in a person’s vision more precisely than did previously available technology. In international markets, the WaveScan System is used in conjunction with our VISX STAR System to perform CustomVue laser vision correction, which enhances laser vision correction and potentially improves vision beyond that of contacts and glasses. In the U.S., we are awaiting FDA approval of our CustomVue^TM procedure.

Page 11 of 23

Results of Operations


		Three Months Ended March 31,

REVENUES (000’s)		2003			2002			Change

System revenues		$	9,926		$	9,915			0	%
	Percent of total revenues		28.8	%		27.1	%
Service and parts revenues			4,830			5,090			(5	)%
	Percent of total revenues		14.0	%		13.9	%
License and other revenues			19,677			21,580			(9	)%
	Percent of total revenues		57.2	%		59.0	%
Total		$	34,433		$	36,585			(6	)%

System revenues

System revenues in the first quarter of 2003 were approximately the same as in the comparable period of the prior year. VISX STAR Laser System revenue declined $1.9 million due principally, we believe, to the economic slowdown in the U.S. and many of our markets abroad. Since approximately 80% of our U.S. customers had upgraded their STAR S2™ laser systems to the STAR S3™ model by the end of 2002, laser upgrade revenue continued to decline, down approximately $0.9 million from the prior year. We anticipate that upgrade revenue throughout 2003 will be significantly lower than in 2002. Sales of our WaveScan System generated approximately $2.8 million of additional sales revenue in the first quarter of 2003 as compared to the same period in 2002 as we continued to extend the rollout of this product.

Service and parts revenues

Service and parts revenues in 2003 were $0.3 million lower than in 2002 due mainly to a new service plan that reduced the price charged for service contracts on laser systems with lower than average procedure volume.

License and other revenues

License and other revenue in the first quarter of 2003 was $1.9 million lower than in the comparable period of 2002 due to a decline in the volume of U.S. procedures for which VISX earned procedure fees.

The U.S. economy has deteriorated over the last two years. One consequence has been a decline in consumers’ discretionary spending. Since laser vision correction surgery is elective and generally not covered by medical insurance, it has been adversely impacted. The volume of laser vision correction surgeries in the U.S. over the past two years has shown a correlation with changes in the stock market and consumer confidence index, both of which have declined significantly during this period. We believe these are the main factors causing the decline in U.S. procedure volume and related revenue. In addition, consumers also consider perceptions about the safety and effectiveness of the procedure. The lack of long-term follow-up studies of the procedure combined with media coverage of selected unfavorable outcomes may have contributed to uncertainty and delay by some potential consumers.

We believe that a rebound in the U.S. economy and increases in consumer confidence will provide renewed support for the U.S. laser vision correction market in the future. We also expect that ongoing technical advances (including our CustomVue™ procedure), which have the potential to improve a person’s vision beyond that which can be obtained with contact lenses or glasses, will reduce concerns

Page 12 of 23

perceived by some consumers regarding the safety of laser vision correction. Notwithstanding, we cannot accurately predict when, or to what extent, these anticipated changes in the economy and technology would impact our license and other revenues.


		Three Months Ended March 31,

COSTS & EXPENSES (000’s)		2003			2002			Change

Cost of system revenues		$	8,295		$	8,181			1	%
	Percent of related revenues		83.6	%		82.5	%
Cost of service and parts revenues			3,697			3,216			15	%
	Percent of related revenues		76.5	%		63.2	%
Cost of license and other revenues			1,193			1,207			(1	)%
	Percent of related revenues		6.1	%		5.6	%


Selling, general and administrative			9,093			10,518			(14	)%
	Percent of total revenues		26.4	%		28.7	%
Research, develop. and regulatory			4,046			4,245			(5	)%
	Percent of total revenues		11.8	%		11.6	%

Cost of system revenues

Cost of system revenues was largely unchanged in the first quarter of 2003 from the corresponding period of the prior year. Sales of lasers and upgrades decreased while shipments of WaveScan Systems increased, but the overall gross profit margin remained fairly level.

Cost of service and parts revenues

Cost of service and parts revenues increased $0.5 million due to higher costs to service a larger installed base of products in the United States.

Cost of license and other revenues

Cost of license and other revenues decreased slightly in the first quarter of 2003 from the corresponding period of the prior year due to the decline in license and other revenue.

Selling, general and administrative expenses

Selling, general and administrative expenses decreased $1.4 million to $9.1 million for the three months ended March 31, 2003 from $10.5 million for the three months ended March 31, 2002. This decrease was primarily due to a reduction in legal expenses of $2.8 million (including $1.5 million due to insurance reimbursements received during the first quarter of 2003 for legal expenses related to litigation between VISX and Nidek) offset partially by an increase in marketing costs of $0.9 million incurred in connection with our new CustomVue™ procedure.

Research, development and regulatory expenses

Research, development and regulatory expenses decreased $0.2 million, to $ 4.0 million for the three months ended March 31, 2003 from $4.2 million for the three months ended March 31, 2002. We continued to focus on next generation technologies and developments for laser vision correction. These included laser platforms such as our STAR S4™ Excimer Laser System, eye diagnostic units such as our WaveScan System, and new methods for correcting vision disorders including our CustomVue procedure and early research and clinical trials on treatments for presbyopia. We also continued funding early stage research at Stanford University for future treatments for age-related macular degeneration (“AMD”) and other advanced technologies. We

Page 13 of 23

anticipate that our research, development and regulatory expenses in 2003 will be consistent with our expenditures in 2002.

Interest and other income

The average yields on our portfolio of cash and investments were lower in 2003 compared to 2002. Accordingly, interest income declined in 2003 from 2002.

Liquidity and Capital Resources

Cash, cash equivalents and short-term investments (“cash”) and working capital were as follows:


	(000’s)
	March 31,		December 31,
	2003		2002

	(Unaudited)
Cash, cash equivalents and short-term investments	$	129,885	$	122,955
Working capital		143,946		138,351
Stockholders’ equity		160,616		155,190

Our cash, cash equivalents, and short-term investments consist principally of money market funds, and government and corporate bonds. All of our short-term investments are classified as “available-for-sale” under the provisions of Statement of Financial Accounting Standards No. 115, “Accounting for Certain Investments in Debt and Equity Securities.” The securities are carried at fair market value with the unrealized gains and losses, net of tax, included in accumulated other comprehensive income, which is reflected as a separate component of stockholders’ equity. Realized gains and losses are recognized when realized on the consolidated statements of operations.

Cash, cash equivalents, and short-term investments increased by $6.9 million in the first quarter of 2003 principally because operating activities provided $7.3 million for the three months ended March 31, 2003.

Net operating activities provided $7.3 million of cash in the first quarter of 2003, down from $20.5 million provided in the first quarter of 2002. The principal factors that contributed to this difference are as follows. Net income decreased by $1.0 million due mainly to lower license revenues. Accounts receivable and inventories increased during 2003, whereas they decreased in 2002, resulting in an $8.3 million change in cash generation. Days sales outstanding in accounts receivable was 68 days at the end of the first quarter of 2003 as compared to 73 days at the comparable point in 2002. Inventory increased in 2003 due to an increase in finished goods. Deferred income tax assets and prepaid expenses decreased in both years due primarily to the utilization of net operating loss carryforwards and a reduction of deferred temporary tax timing differences. The reduction, however, was $1.1 million lower in 2003. Combined, accounts payable and accrued liabilities increased $2.9 million less in 2003 than in 2002 due to timing of payments and higher legal expenses in 2002.

Net cash used in investing activities was $8.2 million in the first quarter of 2003, compared to net cash provided by investing activities of $9.9 million in the first quarter of 2002. Net cash used in investing activities in the first quarter of 2003 consisted primarily of the net investment of cash generated from operations into short-term investments.

Page 14 of 23

Net cash provided by financing activities was $0.1 million in the first quarter of 2003, compared to net cash used in financing activities of $13.7 million in the first quarter of 2002. This difference was due mainly to the fact that $16.2 million was used during the first quarter of 2002 to repurchase 1 million shares of VISX stock in open market transactions, whereas no stock was repurchased during the first quarter of 2003. Partially offsetting these cash expenditures in 2002 was $2.6 million received upon the exercise of stock options. In comparison, virtually no options were exercised in the first quarter of 2003.

On April 4, 2001, our Board of Directors authorized a Stock Repurchase Program under which up to 10 million shares of VISX common stock may be repurchased. In accordance with this authorization and applicable securities laws, we have purchased 7.0 million shares on the open market cumulatively through March 31, 2003. Accordingly, 3.0 million shares remain available for purchase in the future under current Board of Director authorization. Before repurchasing shares we consider a number of factors including market conditions, the market price of the stock, and the number of shares needed for employee benefit plans. As a result, we cannot predict the number of shares that we may repurchase in the future.

Purchases of short-term investments represent reinvestment into short-term investments of the proceeds from short-term investments that matured and investment of cash and cash equivalents. As of March 31, 2003, we did not have any borrowings outstanding nor any credit agreements.

Our normal credit terms granted to customers are net 30 to 60 days. In an effort to promote the growth of the laser vision correction industry and the use of VISX STAR Systems, in certain markets we provide long-term financing to customers for their purchase of our equipment. We consider a number of factors including industry practice, competition, and our evaluation of customers’ credit worthiness in determining when to offer such financing.

We believe that our operations will provide sufficient cash flow to meet our working capital and capital equipment needs during the coming twelve months. In addition, we have $130 million of cash, cash equivalents, and short-term investments as of March 31, 2003 to provide for unforeseen contingencies and to support strategic objectives including the development or acquisition of new technologies and our Stock Repurchase Program.

In May 2002, VISX announced that it entered into an exclusive worldwide license agreement for a portfolio of patents held by Luis Ruiz, MD, relating to the treatment of presbyopia with multifocal ablations. VISX also signed an agreement with Tracey Technologies, LLC for rights to Tracey’s ray tracing technology for use in customized laser vision correction treatments. If clinical and regulatory milestones specified in both agreements were achieved, VISX would be committed to make additional payments of approximately $2 million in connection with these two agreements. VISX could be obligated for royalties in the future based on any future sales of the associated products.

Critical Accounting Policies

We follow accounting principles generally accepted in the United States (“GAAP”) in preparing our financial statements. As part of this work, we must make many estimates and judgments about future events. These affect the value of the assets and liabilities, contingent assets and liabilities, and revenues and expenses that we report in our financial statements. We believe these estimates and judgments are reasonable and we make them in accordance with our accounting policies based on information available at the time. However, actual results could differ from our estimates and this could require us to record adjustments to expenses or revenues that could be material to our financial position and results of

Page 15 of 23

operations in future periods. Our critical accounting policies used in making these estimates and judgments are as follows.

Revenue Recognition

Our revenue is comprised of the following: sale and rental of equipment and upgrades, service revenue, and license fees and related procedure revenue (“procedure revenue”). We recognize revenue in accordance with SEC Staff Accounting Bulletin No. 101, Revenue Recognition in Financial Statements (“SAB 101”). Under this standard, revenue is generally recognized when the following four criteria are met:

	(1)		Persuasive evidence of an arrangement exists;

	(2)		Delivery has occurred or services have been rendered;

	(3)		Our selling price is fixed or determinable; and

	(4)		Collectibility is reasonably assured.

All of our sales are documented by contract or purchase orders specifying sales prices and terms.

We sell directly to end customers in the U.S. Within the U.S. and Japan we directly handle installation of our equipment and upgrades and recognize revenue on these products after we have completed installation at a customer’s site. At this point we accrue an estimate of the cost of warranty service to be provided in the future. Outside the U.S. and Japan our standard terms are FOB VISX and we sell exclusively through independent, third party distributors who are generally responsible for all marketing, sales, installation, training and warranty labor coverage for our products. Accordingly, we recognize system revenue when we ship equipment for customers outside the U.S. and Japan and accrue an estimate of the cost of parts that we are obligated to provide under warranty. Under sales type lease agreements, system revenues are recognized upon shipment or installation, as appropriate. Under rental or operating lease agreements for systems, rental revenue is recognized over the term of the agreement. For customers who purchase service contracts, we recognize service revenue over the term of the contract. Payments received in advance of services performed are recorded as deferred revenue. For customers without service contracts, we recognize service revenue when we provide service. We record spare parts revenue upon shipment of the parts. We recognize license fees and related procedure revenue from direct customers when we ship VisionKey® Cards. We recognize license fees from third party licensees when we receive payment. We classify shipping costs, net of any billings, in cost of revenues.

We assess the credit worthiness of all customers in connection with their purchases. We only recognize revenue when collectibility is reasonably assured. If this is not the case, then we record revenue only as payments are received.

Accounts Receivable

Customers are evaluated for credit worthiness and we recognize revenue when collectibility is reasonably assured. At the end of each accounting period, we estimate the reserve necessary for accounts receivables that will ultimately not be collectible from customers. To develop this estimate, we review all receivables and identify those accounts with problems. For these problem accounts, we estimate individual, specific reserves based on our analysis of the payment history, operations and finances of each account. For all other accounts, we review historical bad debt trends, general and industry specific economic trends, customer concentrations, and current payment patterns to estimate the reserve necessary to provide for

Page 16 of 23

payment defaults that cannot be specifically identified but can be expected with reasonable probability to occur in the future. We face two particular challenges in estimating these reserves: concentration of credit with certain large customers and the potential for significant change in the overall health of the national economies in the markets we serve. Unexpected deterioration in the health of either a large customer or a national economy could lead to a material adverse impact on the collectibility of our accounts receivable and our future operating results.

Inventories

Inventories consist of purchased parts, subassemblies and finished systems and are stated at the lower of cost or market, using the first-in, first-out method. We regularly review our inventory on hand plus on order and compare this to our estimate of demand over the following six months. Based on this analysis, we reduce the carrying value of our inventory for excess and obsolete items. Changes in competition, the economy, and technology can lead to variation in demand for our products. If the change in demand is significant, we may need to further reduce the carrying value of our inventory. All inventory write-downs result in a new cost basis and are charged to cost of revenues, accordingly any inventory write-down would impact our reported cost of revenues.

Legal Contingencies

At the end of each accounting period we review all outstanding legal matters. If we believe it is probable that we will incur a loss as a result of the resolution of a legal matter and we can reasonably estimate the amount of the loss, we accrue our best estimate of the potential loss. It is very difficult to predict the future results of complex legal matters. New developments in legal matters can cause changes in previous estimates and result in significant changes in loss accruals. Currently we are not aware of any legal actions against us or threatened that we believe could materially adversely affect our business, financial condition or results of operations. However, we could in the future be subject to litigation claims that could cause us to incur significant expenses and put our business, financial position, and results of operations at material risk.

Risk Factors

This report contains forward-looking statements that involve risk and uncertainty. The factors set forth below, which are not the only risks we face, may cause our actual results to vary from those contemplated by certain forward-looking statements set forth in this report and should be considered carefully in addition to the other information presented in this report. If any of the following risks actually occur, our business, results of operations or cash flows could be adversely affected. Our results of operations have varied widely in the past, and they could continue to vary significantly. In addition, our actual results may differ significantly from the results contemplated by the forward-looking statements. Accordingly, we believe that our results of operations in any given period may not be a good indicator of our future performance.

Market Acceptance. Our business depends upon broad market acceptance of laser vision correction by both doctors and patients in the United States and key international markets. Laser vision correction has penetrated less than 5% of the eligible U.S. population, and our profitability and continued growth will be largely dependent on increasing levels of market acceptance and procedure growth both in the United States and internationally. Although laser vision correction offers a more predictable outcome and more precise results than other surgical methods used to correct refractive disorders, it is not without risk. Potential complications and side effects include: post-operative discomfort, corneal haze (an increase in the light scattering properties of the cornea) during healing, glare/halos (undesirable visual sensations produced by bright lights), decreases in contrast sensitivity, temporary increases in intraocular pressure in reaction to procedure medication, modest fluctuations in refractive capabilities during healing, modest decrease in best corrected vision (i.e., with corrective eyewear), unintended over- or under-corrections, regression of effect, disorders of corneal healing, corneal scars, corneal ulcers, and induced astigmatism (which may result in blurred or double vision and/or shadow images). Some consumers may not choose to undergo laser vision correction because of these complications or more general concerns relating to its safety and efficacy and a general resistance to surgery. Alternatively, some consumers may elect to delay undergoing laser vision correction surgery because they believe improved technology and/or methods of treatment will be available in the near future. Should either the ophthalmic community or the general population turn away from laser vision correction as an alternative to existing methods of treating refractive vision disorders, or if future technologies replaced laser vision correction, these developments could have a material adverse effect on our business, financial position and results of operations.

Patents and Intellectual Property. Our business is dependent on the enforceability and the validity of our United States and foreign patents. We own over 200 United States and foreign patents and have approximately 180 patent applications pending. Although we are committed to protecting our proprietary technology, it is possible that one or more of our patents will be found to be invalid or unenforceable, or that a party against whom we are asserting claims of patent infringement will be found not to be infringing our patents. Such an outcome could result in, among other things, our inability to sell, license, use or incorporate products that use the challenged technology; increased competition by new or existing competitors or the payment of substantial monetary damages, any of which could have a material adverse effect on our business, financial position and results of operations.

Competition. Intense competition in the laser vision correction industry could result in the loss of customers, an inability to attract new customers, or a decrease in prices for our products. The medical device and ophthalmic laser industries are subject to intense competition and technological change. Not only does laser vision correction compete with more traditional vision correction options such as eyeglasses and contact lenses, it also competes with other technologies and surgical techniques such as corneal implants, intraocular lenses, and surgery using different types of lasers. In addition, the market for laser vision correction systems has become increasingly competitive in recent years as a result of FDA approval of several new laser systems. The VISX System competes with products marketed or under development by other laser and medical equipment manufacturers, many of which have greater financial and other resources. Competitors may offer laser systems at a lower price, may price their laser systems as part of a bundle of products or services, may develop procedures that involve a lower per procedure cost, or may offer products perceived as preferable to the VISX System. In addition, medical companies, academic and research institutions and others could develop new therapies, including new medical devices or surgical procedures, for the conditions targeted by VISX, which therapies could be more medically effective and less expensive than laser vision correction, and could potentially render laser vision correction obsolete. Any such developments could have a material adverse effect on our business, financial position and results of operations.

Unfavorable Side Effects. The possibility of long-term side effects and adverse publicity regarding laser correction surgery could seriously harm our business. Laser vision correction is a relatively new procedure. Consequently, there is no long-term follow-up data beyond ten years, and longer-term follow-up data might reveal additional complications or unknown side effects. Any future reported side effects, other adverse events or unfavorable publicity involving patient outcomes resulting from the use of laser vision correction systems manufactured by VISX or any participant in the laser vision correction market, may have a material adverse effect on our business, financial position, and results of operations.

Economic Conditions. Laser vision correction is not subject to reimbursement from third-party payors such as insurance companies or government programs, and adverse economic conditions have, and may continue to cause, our revenues to decline. The costs of laser vision correction are typically borne by individuals directly. Accordingly, individuals may be less willing to incur the procedure cost associated with laser vision correction in weak or uncertain economic conditions, as was evidenced by our decline in revenues from 2002 compared to 2001 and from 2001 compared to 2000. Any resulting decline in the number of VISX STAR Systems sold or laser vision correction procedures performed may have a material adverse effect on our business, financial position, and results of operations.

Loss Of Significant Customers. If we lose one or more of our significant customers, or if purchases by one or more of our key customers decrease, our net sales may decline and our business could be harmed. A significant portion of our revenues is derived from sales to TLC Vision Corporation (“TLC”) formed in May 2002 through the merger of Laser Vision Centers, Inc. and TLC Laser Eye Centers, Inc., both long-term customers of ours. The combined company, TLC, accounted for 14%, 17% and 18% of our total revenues in 2002, 2001 and 2000, respectively. Should we lose a major customer or if anticipated sales to a major customer do not materialize, our business, financial position and results of operations may suffer.

Fixed Short-Term Expenses. Because our expenses are relatively fixed in the short term, our earnings will decline if we do not meet our projected sales. Any shortfall in revenues below expectations would likely have an immediate impact on our earnings per share, which could adversely affect the market price of our common stock. Our operating expenses, which include sales and marketing, research and development, and general and administrative expenses, are based on our expectations of future revenues and are relatively fixed in the short term. Accordingly, if revenues fall below expectations, we will not be able to reduce our spending rapidly in response to such a shortfall.

Governmental Regulation. We are subject to extensive governmental regulation, which increases our costs and could prevent us from selling our products. Government regulation includes inspection of and controls over research and development, testing, manufacturing, safety and environmental controls, efficacy, labeling, advertising, promotion, pricing, record keeping, the sale and distribution of pharmaceutical products and samples and electronic records and electronic signatures. In the United States, we must obtain FDA approval or clearance for each medical device that we market. The FDA approval process is typically lengthy and expensive, and approval is never certain. Products distributed outside of the United States are also subject to government regulation, which may be equally or more demanding. Our new products could take a significantly longer time than we expect to gain regulatory approval and may never gain approval. If a regulatory authority delays approval of a potentially significant product, our market value and operating results may decline. Even if the FDA or another regulatory agency approves a product, the approval may limit the indicated uses for a product, may otherwise limit our ability to promote, sell and distribute a product or may require post-marketing studies. If we are unable to obtain regulatory approval of our products, we will not be able to market these products, which would result in a decrease in our sales. Currently, we are actively pursuing approval for a number of our products from regulatory authorities in a number of countries, including, among others, the United States, countries in the European Union and Japan. In particular, we are awaiting approval from the FDA to perform our CustomVue™ procedure in the United States. Continued growth in our sales and profits will depend, in part, on the timely and successful introduction and marketing of some or all of these products.

The clinical trials required to obtain regulatory approvals are complex and expensive and their outcomes are uncertain. We incur substantial expense for, and devote significant time to, clinical trials, yet cannot be certain that the trials will ever result in the commercial sale of a product. We may suffer significant setbacks in clinical trials, even after earlier clinical trials show promising results. Any of our products may produce undesirable side effects that could cause us or regulatory authorities to interrupt, delay or halt clinical trials of a product candidate. We, the FDA, or another regulatory authority may suspend or terminate clinical trials at any time if they or we believe the trial participants face unacceptable health risks.

Noncompliance with applicable United States regulatory requirements can result in fines, injunctions, penalties, mandatory recalls or seizures, suspensions of production, denial or withdrawal of pre-marketing approvals, recommendations by the FDA against governmental contracts and criminal prosecution. The FDA also has authority to request repair, replacement, or refund of the cost of any device we manufacture or distribute. Regulatory authorities outside of the United States may impose similar sanctions for noncompliance with applicable regulatory requirements.

Taxes. We operate throughout the United States and, consequently, are subject to various federal, state and local taxes, including sales, income, payroll, unemployment, property, franchise, capital and use tax on our operations, payroll, assets and services. Although we believe we have adequate provisions and accruals in our financial statements for tax liabilities, we cannot predict the outcome of all past and future tax assessments. If any taxing authority determines that we owe amounts for taxes greater than we expect, our earnings may be negatively affected.

New Products May Not Be Commercially Viable. Our research and development may not lead to new products that achieve commercial success. We devote significant resources to research and development. The research and development process is expensive, prolonged, and entails considerable uncertainty. Development of a new product, from discovery through testing and registration to initial product launch, typically takes between three and seven years for a medical device. Each of these periods varies considerably from product to product and country to country. Because of the complexities and uncertainties associated with ophthalmic research and development, products we are currently developing may not complete the development process or obtain the regulatory approvals required to market such products successfully. The products currently in our development pipeline may not be approved by regulatory entities and may not be commercially successful, and our current and planned products could be surpassed by more effective or advanced products.

International Operations. We face risks due to our reliance on sales in international markets. Our future success will depend in part on the continued expansion of our international sales and operations. In particular, during 2002, 2001, and 2000, we derived approximately 23%, 16% and 18%, respectively, of our revenues from sales to customers outside the United States. Our growing international presence exposes us to risks including:

	•		the need for export licenses;

	•		unexpected regulatory requirements;

	•		tariffs and other potential trade barriers and restrictions;

	•		political, legal and economic instability in foreign markets;

	•		longer accounts receivable cycles;

	•		difficulties in managing operations across disparate geographic areas;

	•		foreign currency fluctuations;

	•		reduced or limited protection of our intellectual property rights in some countries; and

	•		dependence on local distributors.

If one or more of these risks materialize, our sales to international customers may decrease and our costs may increase, which could negatively impact our revenues and operating results.

Intellectual Property Disputes. The laser vision correction industry has been the subject of substantial litigation, both in the United States and internationally, specifically focusing on patents and proprietary rights. In the past, our patents have been challenged on several fronts and we have asserted our patents against competitors. Generally, these proceedings centered on whether infringement of the patents had occurred, and on the validity or enforceability of the patents. While all of these proceedings have now been resolved, other companies own United States and foreign patents covering methods and apparatus for performing corneal surgery with ultraviolet lasers. If we were accused of infringing such competitors’ patents, and found to have infringed such patents, we could be subject to significant monetary liability and we could be enjoined from distributing our products. In addition, we may assert our patents against competitors as well. If our patents were found to be invalid or unenforceable (or in the event that parties against whom VISX asserted patent infringement were found not to be infringing our patents), our ability to collect license fees from the parties to the litigation or from other sellers or users of laser vision correction equipment in the United States may suffer and our revenues may decline. Any one of these results could harm our business. See Item 1 “Legal Proceedings” of Part II of this report for additional information regarding legal proceedings involving VISX.

Product Liability Claims. We have and may become subject to product liability claims. We could be liable for injuries or damage resulting from use of the VISX STAR System or WaveScan System. In addition, a claim that an injury resulted from a defect in any VISX product, even if successfully defended, could damage our reputation. Although we possess insurance customarily obtained by businesses of our type (including insurance against product liability risks associated with the testing, manufacturing, and marketing of our products), product liability claims in excess of our insurance coverage could have a material adverse effect on our business, financial position, and results of operations.

Single Sources For Key Components. The manufacture of VISX STAR Systems and WaveScan Systems is a complex operation involving numerous procedures. We depend on single and limited sources for several key components. If any of these suppliers were to cease providing components, we would be required to locate and contract with a substitute supplier. We could have difficulty identifying a substitute supplier in a timely manner or on commercially reasonable terms. If the production of our products, parts and services were interrupted or could not continue in a cost-effective or timely manner, our business, financial position, and results of operations, could be materially adversely affected.

Volatility of our Stock Price. The market price of our common stock has experienced fluctuations and is likely to fluctuate significantly in the future. Our stock price can fluctuate for a number of reasons, including:

	•		announcements about us or our competitors;

	•		results or settlements of any litigation;

	•		quarterly variations in operating results;

	•		the introduction or abandonment of new technologies or products;

	•		changes in product pricing policies by us or our competitors;

	•		changes in earnings estimates by analysts or changes in accounting policies; and

	•		economic changes and political uncertainties.

In addition, stock markets have experienced significant price and volume volatility in recent years. This volatility has had a substantial effect on the market prices of securities of many public companies for reasons frequently unrelated or disproportionate to the operating performance of the specific companies. In addition, the securities of many medical device companies, including VISX, have historically been subject to extensive price and volume fluctuations that may affect the market price of their common stock. If these broad market fluctuations continue, they may adversely affect the market price of our common stock.

Confidentiality Agreements. We rely on confidentiality agreements to protect our proprietary technology. We protect our proprietary technology, in part, through confidentiality and nondisclosure agreements with employees, consultants and other parties. Our confidentiality agreements with employees and consultants generally contain standard provisions requiring those individuals to assign to us, without additional consideration, inventions conceived or reduced to practice by them while employed or retained by us, subject to customary exceptions. If any of our employees, consultants or others breach these confidentiality agreements, we may not have adequate remedies for any breach, and our competitors may learn of our trade secrets.

New Technologies. If we fail to keep pace with advances in our industry or fail to develop new methods of vision correction, customers may not buy our products and our revenue may decline. We must be able to manufacture and effectively market those products and persuade a sufficient number of eye care professionals to use the new products we introduce. Sales of our existing products may decline rapidly if a new product is introduced by one of our competitors or if we announce a new product that, in either case, represents a substantial improvement over our existing products. A decrease in procedure volume may also occur if consumers elect to delay undergoing laser vision correction surgery because they believe improved technology and/or methods of treatment will be available in the near future.

Antitakeover Provisions in Our Charter Documents. In 2000, we adopted a stockholder rights plan. The presence of this plan could make it more difficult for a third party to engage in a takeover attempt, even a takeover attempt in which the potential purchaser offers to pay a per share price greater than the current market price for our common stock. In addition, the presence of the plan could delay or impede the removal of incumbent directors. These provisions may also impact the amount of interest investors have in our business.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

There were no material changes during the three months ended March 31, 2003 in our exposure to market risk for changes in interest rates and foreign currency exchange rates.

Item 4. Disclosure Controls and Procedures

VISX management, including the Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of disclosure controls and procedures (as defined in Exchange Act Rule 13a-14(c) and 15d-14(c)) within 90 days as of the filing date of this quarterly report (the “Evaluation Date”). Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures are effective in ensuring that all material information required to be filed in this quarterly report has been made known to them in a timely fashion. There have been no significant changes in internal controls, or in factors that could significantly affect internal controls, subsequent to the Evaluation Date.

Page 17 of 23

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Overview

From time to time, we have been involved in a variety of legal proceedings. For a complete description of legal proceedings, see our annual report on Form 10-K for the year ended December 31, 2002. During the quarter ended March 31, 2003, there were no material developments with respect to such previously existing proceedings and no new material proceedings not previously disclosed, except as follows.

Patent Litigation: Nidek and Users of Nidek Lasers

On March 31, 2003, VISX and Nidek signed a term sheet outlining a global litigation settlement and patent cross-license. On April 4, 2003, VISX and Nidek concluded the settlement by signing final settlement and cross-license agreements. As a result of the signing of the March 31, 2003 term sheet, we concluded that a final settlement was probable and accrued a $9 million charge for litigation settlement expense in our financial statements for 2002.

Pursuant to the settlement, the following lawsuits have been or will be dismissed:

United States

In re Nidek Excimer Laser Surgery Systems Patent & Antitrust Litigation (USDC ND Cal, MDL No. 1319), which consisted of the following actions consolidated for pre-trial proceedings:

		VISX, Incorporated v. Nidek Co., Ltd., et al. (USDC ND Cal, C98-4842-CRB). As a result of the settlement, this action was dismissed without prejudice.

		Nidek Co., Ltd., et al. v. VISX, Incorporated (USDC ND Cal C99-1528-CRB). As a result of the settlement, this action was dismissed with prejudice.

		VISX, Incorporated v. Farmington Eye Center PLLC, et al. (USDC ED Mich 99-60139; and USDC ND Cal C00-0870-CRB). As a result of the settlement, this action was dismissed without prejudice.

		VISX, Incorporated v. Antoine L. Garabet, M.D., Inc., et al. (USDC CD Cal 99-05284; and USDC ND Cal C00-0868-CRB). As a result of the settlement, this action was dismissed without prejudice.

		VISX, Incorporated v. Refractive Support, Inc., et al. (USDC ND Ohio 1:99CV00508; and USDC ND Cal C00-0871-CRB). As a result of the settlement, our claims and defendants’ declaratory relief claims were dismissed without prejudice, and defendants’ damages claims were dismissed with prejudice.

		VISX, Incorporated v. Southwest Eye Care Center, Inc., et al. (USDC SD Cal 99 CV 1029L; and USDC ND Cal C00-0869-CRB). As a result of the settlement, our claims and defendants’ declaratory relief claims were dismissed without prejudice, and defendants’ damages claims were dismissed with prejudice.

Page 18 of 23

Nidek Co., Ltd. v. VISX, Incorporated (USDC ND Cal C01-20015 JF). As a result of the settlement, this action was dismissed without prejudice.

Canada, France and Japan

As a result of the settlement, the parties resolved certain court costs issues that were still pending in their Canadian litigation. As a further result of the settlement, our patent infringement action against Nidek in France will be dismissed with prejudice, and our patent invalidity proceedings and Nidek’s patent infringement action in Japan were withdrawn, rendering Nidek’s Japanese appeals moot.

While we are involved in litigation arising periodically in the ordinary course of business, we are not aware of any actions against us that we believe would materially adversely affect our business, financial condition or results of operations. However, in the future we could be subject to litigation claims that could cause us to incur significant expenses.

Item 5. Other Information

In accordance with Section 10A(i)(2) of the Securities Exchange Act of 1934, as added by Section 202 of the Sarbanes-Oxley Act of 2002, VISX is responsible for disclosing the non-audit services approved by VISX ’s Audit Committee to be performed by KPMG LLP, VISX ’s independent auditor. Non-audit services are defined in the law as services other than those provided in connection with an audit or a review of the financial statements of VISX. The non-audit services approved by the Audit Committee in the first quarter are considered by VISX to be audit-related services that closely relate to the financial audit process. Each of the services has been approved in accordance with a pre-approval from the Audit Committee’s Chairman pursuant to delegated authority by the Audit Committee.

During the quarterly period covered by this filing, the Committee approved additional engagements of KPMG LLP for the following non-audit service: tax return preparation, non-audit accounting services, and tax matter consultations concerning federal and state taxes.

Item 6. Exhibits and Reports on Form 8-K

a)		Exhibits.

		99.1 Certification of Chief Executive Officer and Chief Financial Officer

b)		Reports on Form 8-K.

		None

Page 19 of 23

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		VISX, Incorporated

		(Registrant)

May 12, 2003		/s/ Elizabeth H. Dávila
(Date)
		Elizabeth H. Dávila
		Chairman of the Board and
		Chief Executive Officer

May 12, 2003		/s/ Timothy R. Maier
(Date)
		Timothy R. Maier
		Executive Vice President and
		Chief Financial Officer (principal
		financial officer)

May 12, 2003		/s/ Derek A. Bertocci
(Date)
		Derek A. Bertocci
		Vice President, Controller (principal
		accounting officer)

Page 20 of 23

CERTIFICATION

I, Elizabeth H. Dávila, certify that:

1.		I have reviewed this quarterly report on Form 10-Q of VISX, Incorporated;

2.		Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.		Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4.		The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

	a)		designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

	b)		evaluated the effectiveness of the registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the “Evaluation Date”); and

	c)		presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

	a)		all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and

	b)		any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls; and

The registrant’s other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.


	/s/ Elizabeth H. Dávila

	Elizabeth H. Dávila
	Chief Executive Officer
	May 12, 2003

Page 21 of 23

CERTIFICATION

I, Timothy R. Maier, certify that:

1.		I have reviewed this quarterly report on Form 10-Q of VISX, Incorporated;

2.		Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.		Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4.		The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

	a)		designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

	b)		evaluated the effectiveness of the registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the “Evaluation Date”); and

	c)		presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

the registrant’s other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

	a)		all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and

	b)		any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls; and


	/s/ Timothy R. Maier

	Timothy R. Maier
	Chief Financial Officer
	May 12, 2003

Page 22 of 23

EXHIBIT INDEX

99.1

Certification of Chief Executive Officer and Chief Financial Officer

Page 23 of 23

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents